Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...
Business Wire·14d ago
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded Estrella Immunopharma to a "hold" rating in a research note on Saturday...
MarketBeat·26d ago
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.